RNS Number : 2267E
Omega Diagnostics Group PLC
26 October 2022
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Result of AGM

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that all resolutions were duly passed on a show of hands at the Annual General Meeting held earlier today.

 

The proxy results are set out below:

 

Resolution

For

Against

Discretion to Chairman 

Withheld

Total

1

34,356,590

40,050

782

43,849

34,441,271

2

34,216,465

136,716

782

87,308

34,441,271

3

33,966,638

387,493

782

86,358

34,441,271

4

29,439,574

4,242,865

282

758,050

34,441,271

5

33,731,138

551,301

782

158,050

34,441,271

6

33,073,535

745,352

782

621,602

34,441,271

7

32,488,609

1,315,685

2,032

634,945

34,441,271

 

 

Contacts: 

 

Omega Diagnostics Group PLC                         

www.omegadiagnostics.com

Jag Grewal, Chief Executive                             

via Walbrook PR

Chris Lea, Chief Financial Officer




finnCap Ltd                                              

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)


Alice Lane/ Charlotte Sutcliffe (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Sam Allen / Lianne Applegarth

Mob: 07980 541 893 / 07502 558 258 / 07584 391 303

 

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFEUFDMEESELS